Pacific Biosciences of California, Inc. (PACB)
收市後：
Pacific Biosciences of California, Inc.
1305 O’Brien Drive
Menlo Park, CA 94025
United States
650 521 8000
https://www.pacb.com
版塊: Healthcare
行業: Medical Devices
全職員工: 796
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Christian O. Henry M.B.A. | President, CEO & Director | 1.1M | 無 | 1968 |
| Ms. Susan G. Kim | Chief Financial Officer | 564.87k | 無 | 1976 |
| Mr. Mark Van Oene | Chief Operating Officer | 772.11k | 無 | 1973 |
| Mr. Jeff Eidel | Chief Commercial Officer | 435.62k | 無 | 1977 |
| Dr. Stephen Turner Ph.D. | Co-Founder | 341.25k | 無 | 1968 |
| Trevin Rard | Head of Investor Relations | 無 | 無 | 無 |
| Dr. Brett Atkins J.D., Ph.D. | General Counsel & Corporate Secretary | 無 | 無 | 無 |
| Ms. Natalie Welch | Chief People Officer | 無 | 無 | 無 |
| Dr. Denis Zaccarin Ph.D. | Senior Vice President of Research & Development | 510.77k | 4.34M | 1966 |
| Mr. Mike Goloubef | Senior Vice President of Manufacturing & Quality | 無 | 無 | 無 |
描述
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
公司管治
截至 2024年4月1日 止，Pacific Biosciences of California, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：6；董事會：3；股東權利：4；現金賠償：7。
